Janney Montgomery Scott LLC Cuts Stock Position in ADMA Biologics Inc $ADMA

Key Points

• Janney Montgomery Scott LLC has reduced its stake in ADMA Biologics Inc by 27.7%, selling 19,644 shares and now holding 51,347 shares valued at approximately $935,000.
• ADMA Biologics reported a quarterly earnings per share of $0.15, exceeding the consensus estimate of $0.14, with revenues rising by 13.8% year-over-year.
• Weiss Ratings has reaffirmed a buy (b-) rating on ADMA Biologics, with a consensus target price of $27.67 among analysts.

Janney Montgomery Scott LLC cut its holdings in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 27.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 51,347 shares of the biotechnology company's stock after selling 19,644 shares during the quarter. Janney Montgomery Scott LLC's holdings in ADMA Biologics were worth $935,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of ADMA. Farther Finance Advisors LLC grew its holdings in shares of ADMA Biologics by 1,149.1% in the first quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 2,505 shares in the last quarter. GAMMA Investing LLC boosted its stake in ADMA Biologics by 251.6% during the first quarter. GAMMA Investing LLC now owns 6,589 shares of the biotechnology company's stock worth $131,000 after buying an additional 4,715 shares during the period. Envestnet Portfolio Solutions Inc. purchased a new position in ADMA Biologics during the first quarter worth $240,000. PFG Investments LLC boosted its stake in ADMA Biologics by 0.6% during the first quarter. PFG Investments LLC now owns 222,809 shares of the biotechnology company's stock worth $4,421,000 after buying an additional 1,301 shares during the period. Finally, Ausbil Investment Management Ltd boosted its stake in ADMA Biologics by 1,215.1% during the first quarter. Ausbil Investment Management Ltd now owns 106,869 shares of the biotechnology company's stock worth $2,120,000 after buying an additional 98,743 shares during the period. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Stock Up 2.7%

Shares of ADMA opened at $14.95 on Wednesday. The firm has a market capitalization of $3.57 billion, a P/E ratio of 17.38 and a beta of 0.47. ADMA Biologics Inc has a 12-month low of $13.50 and a 12-month high of $25.67. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. The firm has a fifty day moving average price of $16.15 and a 200-day moving average price of $18.47.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.01. The firm had revenue of $121.98 million during the quarter, compared to the consensus estimate of $121.77 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The firm's quarterly revenue was up 13.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.13 earnings per share. Equities research analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a "buy (b-)" rating on shares of ADMA Biologics in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $27.67.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.